Amgen (AMGN) Financials: History & Chart

Amgen Inc. (AMGN)AMGNAmgen Inc.

About Amgen Inc.

Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.

Thousand Oaks, CA

31,500 employees

www.amgen.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Robert A. Bradway

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024	Quarter ended Jun 2024
Revenue	37.24B	8.62B	9.90B	9.56B	9.17B	8.15B	9.09B	8.50B	8.39B
Cost of Goods Sold	10.63B	2.74B	1.79B	3.08B	3.01B	2.97B	3.11B	3.31B	3.24B
Gross Profit	26.61B	5.87B	8.11B	6.47B	6.16B	5.18B	5.97B	5.19B	5.15B
Gross Profit Margin	71.5%	68.2%	81.9%	67.8%	67.2%	63.6%	65.7%	61.1%	61.4%
Total Operating Expenses	14.83B	3.21B	4.16B	3.95B	3.51B	4.00B	3.66B	3.15B	3.24B
Research & Development	7.51B	1.72B	2.15B	1.90B	1.74B	1.49B	1.72B	1.45B	1.45B
Selling, General & Administrative	6.95B	1.60B	1.94B	1.72B	1.69B	1.69B	1.88B	1.63B	1.78B
Operating Income (EBIT)	11.78B	2.67B	3.94B	2.53B	2.64B	1.18B	2.31B	2.05B	1.91B
Operating Margin	31.6%	30.9%	39.8%	26.4%	28.8%	14.5%	25.4%	24.1%	22.8%
Income Before Tax (EBT)	9.09B	2.08B	1.51B	3.92B	1.57B	1.97B	782.00M	3.10B	794.00M
Interest Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	2.70B	657.00M	653.00M	685.00M	708.00M	723.00M	747.00M	776.00M	808.00M
Other Income/Expense	-2.69B	-582.00M	-2.43B	1.40B	-1.08B	795.00M	-1.53B	1.05B	-1.11B
Net Income	7.80B	1.82B	1.33B	3.22B	1.43B	1.73B	627.00M	2.83B	746.00M
Income Tax Expense	1.29B	265.00M	181.00M	705.00M	136.00M	243.00M	155.00M	271.00M	48.00M
Net Profit Margin	20.9%	21.1%	13.5%	33.7%	15.6%	21.2%	6.9%	33.3%	8.9%
EBITDA	16.67B	3.78B	5.07B	3.83B	3.98B	2.56B	3.71B	3.44B	3.31B
EBITDA Margin	44.8%	43.9%	51.3%	40.1%	43.5%	31.5%	40.8%	40.5%	39.4%
Depreciation & Amortization	4.90B	1.12B	1.13B	1.31B	1.34B	1.39B	1.40B	1.40B	1.40B
EPS Basic	14.48	3.37	2.47	5.98	2.66	3.22	1.17	5.27	1.39
EPS Diluted	14.37	3.34	2.45	5.93	2.65	3.20	1.16	5.22	1.38
Shares Outstanding	540.00M	540.00M	539.00M	538.00M	538.00M	538.00M	540.52M	537.00M	537.00M
Diluted Shares Outstanding	544.00M	544.00M	543.00M	542.00M	541.00M	541.00M	542.00M	542.00M	541.00M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	36.74B	33.42B	28.19B	26.32B	25.98B	25.42B	23.36B	23.75B
Cost of Goods Sold	10.73B	12.86B	8.41B	6.41B	6.45B	6.16B	4.36B	4.10B
Gross Profit	26.01B	20.57B	19.77B	19.92B	19.52B	19.27B	19.01B	19.65B
Gross Profit Margin	70.8%	61.5%	70.1%	75.7%	75.2%	75.8%	81.4%	82.7%
Total Operating Expenses	15.34B	13.31B	11.84B	10.35B	11.89B	10.13B	9.33B	9.38B
Research & Development	6.97B	5.96B	4.78B	4.43B	6.32B	4.21B	4.12B	3.74B
Selling, General & Administrative	7.05B	7.10B	6.18B	5.41B	5.37B	5.73B	5.15B	5.33B
Operating Income (EBIT)	10.68B	7.26B	7.90B	9.57B	7.64B	9.14B	9.67B	10.26B
Operating Margin	29.1%	21.7%	28.0%	36.3%	29.4%	35.9%	41.4%	43.2%
Income Before Tax (EBT)	8.98B	4.61B	7.86B	7.35B	6.70B	8.13B	9.14B	9.54B
Interest Income	N/A	N/A	N/A	N/A	N/A	N/A	587.00M	674.00M
Interest Expense	2.75B	3.15B	2.88B	1.41B	1.20B	1.26B	1.29B	1.39B
Other Income/Expense	-1.70B	-2.65B	-42.00M	-2.22B	-938.00M	-1.01B	-536.00M	-718.00M
Net Income	7.71B	4.09B	6.72B	6.55B	5.89B	7.26B	7.84B	8.39B
Income Tax Expense	1.26B	519.00M	1.14B	794.00M	808.00M	869.00M	1.30B	1.15B
Net Profit Margin	21.0%	12.2%	23.8%	24.9%	22.7%	28.6%	33.6%	35.3%
EBITDA	15.84B	12.85B	11.97B	12.98B	11.04B	12.74B	11.88B	12.21B
EBITDA Margin	43.1%	38.4%	42.5%	49.3%	42.5%	50.1%	50.9%	51.4%
Depreciation & Amortization	5.17B	5.59B	4.07B	3.42B	3.40B	3.60B	2.21B	1.95B
EPS Basic	14.33	7.62	12.56	12.18	10.34	12.40	12.96	12.70
EPS Diluted	14.23	7.56	12.49	12.11	10.28	12.31	12.88	12.62
Shares Outstanding	538.00M	541.00M	535.00M	538.00M	570.00M	586.00M	605.00M	661.00M
Diluted Shares Outstanding	542.00M	541.00M	538.00M	541.00M	573.00M	590.00M	609.00M	665.00M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.